Mastectomy numbers on the rise in women eligible for lumpectomy

This article originally appeared here.
Mastectomy Rates Rising Among Women Eligible for Lumpectomy
Mastectomy Rates Rising Among Women Eligible for Lumpectomy

(HealthDay News) -- A rising number of early-stage breast cancer patients who are eligible for lumpectomy are nonetheless undergoing mastectomy, according to a study published online Nov. 19 in JAMA Surgery.

Researchers led by Kristy Kummerow, M.D., of the Vanderbilt University Medical Center in Nashville, Tenn., tracked data from the National Cancer Data Base. They found that the percentage of early-stage breast cancer patients who were eligible for breast conservation surgery but underwent mastectomy rose from 34.3 percent in 1998 to 37.8 percent in 2011. The largest increases were among patients with lymph node-negative, contained cancers.

Kummerow's team found that younger women were more likely to have a mastectomy regardless of tumor size, while older women were more likely to undergo mastectomy if they had a tumor larger than 2 cm. Rates of double mastectomy when cancer had only been detected in one breast also rose -- from 1.9 percent in 1998 to 11.2 percent in 2011, and rates of double mastectomy for early-stage cancer in one breast increased from 5.4 percent of mastectomies in 1998 to 29.7 percent in 2011. Rates of breast reconstruction among women undergoing mastectomy rose from 11.6 percent in 1998 to 36.4 percent in 2011, while rates of breast reconstruction among women who had a double mastectomy for early-stage cancer in one breast increased from 36.9 to 57.2 percent.

One expert believes there may be many reasons driving the trend. "While we have known for quite a long time now that survival from breast cancer is equivalent comparing lumpectomy with mastectomy, there are clearly other forces -- such as aesthetics, genetics, and anxiety related to future screening -- that are also driving surgical decision-making, especially for younger women with breast cancer," Elisa Port, M.D., chief of breast surgery and co-director of the Dubin Breast Center at The Tisch Cancer Institute in New York City, told HealthDay. Port was not involved in the new research.

Full Article
Abstract
Full Text
Editorial (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs